Created at Source Raw Value Validated value
Oct. 26, 2020, 11:31 p.m. usa

- known hypersensitivity to hcq or other 4-aminoquinoline compounds - known hypersensitivity to azithromycin or other azalide or macrolide antibiotics - currently hospitalized - signs of respiratory distress prior to randomization, including respiratory rate >24 - current medications include hcq - concomitant use of other anti-malarial treatment or chemoprophylaxis - history of retinopathy of any etiology - psoriasis - porphyria - chronic kidney disease (stage iv or receiving dialysis) - known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes <1500) or thrombocytopenia (<100 k) - concomitant use of digoxin, cyclosporin, cimetidine, amiodarone, or tamoxifen - known cirrhosis - known personal or family history of long qt syndrome - history of coronary artery disease with a history of graft or stent - history of heart failure, class 2 or greater using the new york heart association functional class - taking medications associated with prolonged qt and known risk of torsades de points. these medications may include some antipsychotic and antidepressant medications. (lopinavir-ritonavir platform) - taking medications associated with prolonged qt such as antipsychotic medications or antidepressants (e.g., citalopram, venlafaxine, and bupropion) and unable to stop during the trial - taking warfarin (coumadin or jantoven) - known history of glucose-6-phosphate-dehydrogenase deficiency - history of myasthenia gravis

- known hypersensitivity to hcq or other 4-aminoquinoline compounds - known hypersensitivity to azithromycin or other azalide or macrolide antibiotics - currently hospitalized - signs of respiratory distress prior to randomization, including respiratory rate >24 - current medications include hcq - concomitant use of other anti-malarial treatment or chemoprophylaxis - history of retinopathy of any etiology - psoriasis - porphyria - chronic kidney disease (stage iv or receiving dialysis) - known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes <1500) or thrombocytopenia (<100 k) - concomitant use of digoxin, cyclosporin, cimetidine, amiodarone, or tamoxifen - known cirrhosis - known personal or family history of long qt syndrome - history of coronary artery disease with a history of graft or stent - history of heart failure, class 2 or greater using the new york heart association functional class - taking medications associated with prolonged qt and known risk of torsades de points. these medications may include some antipsychotic and antidepressant medications. (lopinavir-ritonavir platform) - taking medications associated with prolonged qt such as antipsychotic medications or antidepressants (e.g., citalopram, venlafaxine, and bupropion) and unable to stop during the trial - taking warfarin (coumadin or jantoven) - known history of glucose-6-phosphate-dehydrogenase deficiency - history of myasthenia gravis